Cargando…

The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis

BACKGROUND: Fluoroquinolone is recommended as a pivotal antituberculous agent for treating multi-drug-resistant pulmonary tuberculosis. However, its effectiveness as first-line treatment remains controversial. The present study was conducted to validate the fluoroquinolone-containing regimen for dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyun Woo, Lee, Jung Kyu, Kim, Eunyoung, Yim, Jae-Joon, Lee, Chang-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959712/ https://www.ncbi.nlm.nih.gov/pubmed/27455053 http://dx.doi.org/10.1371/journal.pone.0159827

Ejemplares similares

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study
por: Min, Jinsoo, et al.
Publicado: (2022)

Efficacy and safety of fluoroquinolone-containing regimens in treating pulmonary Mycobacterium avium complex disease: A propensity score analysis
por: Shuto, Hisayuki, et al.
Publicado: (2020)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
por: Schwalb, Alvaro, et al.
Publicado: (2021)

Effectiveness and safety of Levofloxacin containing regimen in the treatment of Isoniazid mono-resistant pulmonary Tuberculosis: a systematic review
por: Inbaraj, Leeberk Raja, et al.
Publicado: (2023)

A Bibliometric Analysis on Tuberculosis Research of Korea from 1979 to 2017
por: Lee, Hyun Woo, et al.
Publicado: (2019)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

The Interval Between Initiation of Anti-tuberculosis Treatment in Patients with Culture-positive Pulmonary Tuberculosis and Receipt of Drug-susceptibility Test Results
por: Joh, Joon-Sung, et al.
Publicado: (2007)

Impact of sputum gross appearance and volume on smear positivity of pulmonary tuberculosis: a prospective cohort study
por: Yoon, Soon Ho, et al.
Publicado: (2012)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis
por: Veziris, Nicolas, et al.
Publicado: (2011)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
por: Kim, Bo-Guen, et al.
Publicado: (2020)

1495. Fluoroquinolone as an Alternative Regimen for Klebsiella pneumoniae Liver Abscess
por: Chuang, Chien, et al.
Publicado: (2019)

Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
por: Bygrave, Helen, et al.
Publicado: (2011)

Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions
por: Shen, Gwan-Han, et al.
Publicado: (2012)

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients
por: Kabir, Saba, et al.
Publicado: (2020)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
por: Pranger, A. D., et al.
Publicado: (2019)

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis
por: Olliaro, Piero L., et al.
Publicado: (2017)

Predictors of Success of Repeated Injections of Single-dose Methotrexate Regimen for Tubal Ectopic Pregnancy
por: Cho, Geum Joon, et al.
Publicado: (2006)

Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
por: Shrestha, Sourya, et al.
Publicado: (2014)

Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
por: Zheng, Xubin, et al.
Publicado: (2023)

High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India
por: Sharma, Rohini, et al.
Publicado: (2019)

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
por: Pillay, Samantha, et al.
Publicado: (2022)

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial
por: Lee, Ji Yeon, et al.
Publicado: (2017)

The Association Between Bacille Calmette-Guérin Vaccination and Nontuberculous Mycobacterial Pulmonary Disease
por: Kwak, Nakwon, et al.
Publicado: (2022)

Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea
por: Choi, Seung Yong, et al.
Publicado: (2018)

Patterns of Fluoroquinolone Prescribing at a Tuberculosis Hospital
por: Kizilbash, Quratulain, et al.
Publicado: (2017)

Fluoroquinolone Derivatives in the Treatment of Mycobacterium tuberculosis Infection
por: Pais, João Pedro, et al.
Publicado: (2022)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
por: Lee, Myungsun, et al.
Publicado: (2019)

Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections
por: Ahn, Hyo Jun, et al.
Publicado: (2017)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

1115. Use of a Fluoroquinolone (FQ) vs. a Non-Fluoroquinolone (Non-FQ)-Based Antibiotic Regimen in the Treatment of Acute, Uncomplicated Diverticulitis
por: Mourani, Jessyca, et al.
Publicado: (2018)

Culture Conversion Rate at 2 Months of Treatment According to Diagnostic Methods among Patients with Culture-Positive Pulmonary Tuberculosis
por: Lee, Ha Youn, et al.
Publicado: (2014)

Serial interferon-gamma release assays during treatment of active tuberculosis in young adults
por: Lee, Sei Won, et al.
Publicado: (2010)

Fluoroquinolone-Resistant Mycobacterium tuberculosis, Pakistan, 2005–2009
por: Jabeen, Kauser, et al.
Publicado: (2011)

The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016
por: Murray, Hugh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ri5fe5jliuj8mmo4q81mbocbsm